End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
156.6 CNY | -0.89% | +2.35% | -8.97% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With an expected P/E ratio at 42.35 and 30.66 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.97% | 2.28B | - | ||
-11.58% | 21.14B | B | ||
+2.04% | 17.59B | A | ||
+10.47% | 10.13B | B- | ||
+5.28% | 1.8B | B+ | ||
+34.04% | 1.65B | D- | ||
+24.42% | 652M | - | ||
0.00% | 385M | - | - | |
+29.81% | 150M | - | ||
+23.55% | 93.16M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688050 Stock
- Ratings Eyebright Medical Technology (Beijing) Co., Ltd.